remogliflozin etabonate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. Remogliflozin was commercially launched first in India by Glenmark in May 2019.   Wikipedia

Chemistry

  • SMILES: CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc3ccc(OC(C)C)cc3)[C@H](O)[C@@H](O)[C@@H]1O
  • InChIKey: UAOCLDQAQNNEAX-ABMICEGHSA-N
  • Mol. Mass: 522.6
  • ALogP: 2.51
  • ChEMBL Molecule:
    remogliflozin etabonate  
More Chemistry

Pharmacology

Alternative names

gsk189075 | gsk189075a | remogliflozin etabonate

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Obesity (Phase 1)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue